查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466523

糖尿病神經病變市場：依治療類型、疾病類型、通路分類 - 全球預測 2024-2030

Diabetic Neuropathy Market by Treatment Type (Drugs, Physiotherapy), Disorder Type (Autonomic Neuropathy, Focal Neuropathy, Peripheral Neuropathy), Distribution channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年糖尿病神經病變市場規模為35億美元，預計2024年將達37.2億美元，2030年將達54億美元，複合年成長率為6.37%。

糖尿病神經病變是一種損害神經的疾病，發生在糖尿病患者身上。高血糖（葡萄糖）會損害全身的神經，但糖尿病神經病變最常影響腿部和臀部的神經。對糖尿病神經病變有效治療、糖尿病診斷的需求不斷成長，以及政府的多項措施是糖尿病神經病變市場成長的主要驅動力。此外，人們對糖尿病神經病變認知的提高、醫療保健支出的增加以及醫藥品研究開發費用的增加都有助於開發治療糖尿病神經病變的新藥物和系統。然而，用於治療糖尿病神經病變的藥物價格昂貴，且替代療法的可用性可能會限制糖尿病患者的使用。先進藥物輸送系統的生產和糖尿病神經病變研究的不斷增加將導致突破性系統的開發，以有效管理糖尿病神經病變狀況，並在預測期內加速患者的使用

主要市場統計
基準年[2023] 35億美元
預測年份 [2024] 37.2億美元
預測年份 [2030] 54億美元
複合年成長率（%） 6.37%

治療類型：糖尿病神經病變的藥物治療廣泛使用藥物來緩解疼痛和穩定神經功能。

糖尿病神經病變的藥物治療使用藥物來減輕疼痛和穩定神經功能。Pregabalin(Lyrica) 和Gabapentin(Neurontin) 是抗驚厥藥，常用於治療糖尿病神經病變患者的神經疼痛。在鴉片類藥物中，曲馬多（Ultram）是一種中樞作用的鴉片類鎮痛藥，用於治療與糖尿病神經病變相關的中度至重度疼痛。物理治療又稱物理治療，是一種提升糖尿病神經病變患者的功能能力、緩解疼痛的非藥物治療方法。由經過認證的物理治療師監督的定期運動和力量訓練計劃可以幫助糖尿病神經病變患者提高力量、平衡和耐力。通常優選物理治療以避免副作用和禁忌症。

疾病類型 由於神經病變盛行率增加，糖尿病神經病變優先

自主神經病變影響自主神經系統，自主神經系統控制內臟器官的不自主功能。患有這種疾病的患者會出現心律不整、排尿困難、消化器官系統問題和性功能障礙。根據個人需要，治療可能包括調節血壓和心率的藥物、控制胃腸蠕動的藥物以及治療勃起功能障礙的藥物。局部神經病變是一種單一神經或一組神經受損的疾病，導致身體特定部位（例如手、腳或軀幹）的劇烈疼痛和無力。治療方法針對根本原因，例如壓迫或卡壓，包括針對腕隧道症候群的夾板和矯正器具，以及針對嚴重病例的手術介入。週邊神經病變是最常見的類型，影響手臂、手、腳和腿的神經。症狀包括麻木、刺痛、疼痛和虛弱。治療方法根據個人需求而有所不同，包括非處方止痛藥和處方藥。近端神經病變主要影響臀部、臀部和大腿的肌肉，症狀包括劇烈疼痛和肌肉無力。

通路：網路藥局的出現成為糖尿病神經病變治療藥物的便捷通路。

糖尿病神經病變患者喜歡由內分泌科醫生、足病醫生和糖尿病教育工作者等專家團隊提供專門護理的診所，因為其方便、實惠且可及。該醫院為糖尿病神經病變患者提供全面護理，這些患者因感染疾病或潰瘍等嚴重併發症而需要更廣泛的治療或緊急干預。醫院擁有擅長治療複雜病例的設備和多學科團隊。網路藥局已成為治療糖尿病神經病變藥物（如止痛藥、抗驚厥藥和抗憂鬱症）的便捷通路。網路藥局受到患者的青睞，因為與零售藥局相比，它們更容易使用，有更謹慎的交付選擇，價格更具競爭力。零售藥局很受歡迎，可以購買治療糖尿病神經病變的藥物和非處方補充品。零售藥局的優勢在於能夠與藥劑師面對面，獲得個人化建議和藥物管理支持，並可以獲得多種產品。

區域洞察

由於糖尿病患者數量不斷增加以及對該疾病的認知不斷增強，美洲成為糖尿病神經病變的重要市場。 FDA 對新產品開發的核准以及開發新的有效藥物的持續研究工作是美洲地區的主要成長要素。由於藥物開發的研發活動活性化，亞太地區代表了全球糖尿病神經病變市場的成長。在亞太地區，有幾家新興企業專注於開發糖尿病神經病變治療藥物，為市場成長做出了貢獻。政府加強支持力度，提高人們對糖尿病管理的認知，以及用於緩解疼痛和有效管理糖尿病神經病變病變症狀的新藥物和系統的研發，這將導致歐洲、中東和非洲地區糖尿病神經病變病變藥物和系統的供應量增加，這提供了巨大的擴張潛力。此外，創新治療方法和藥物傳輸系統的引入預計將有助於糖尿病神經病變市場的全球成長。

FPNV定位矩陣

FPNV定位矩陣對於評估糖尿病神經病變市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對糖尿病神經病變市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.糖尿病神經病變市場的市場規模與預測為何？

2.在糖尿病神經病變市場的預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？

3.糖尿病神經病變市場的技術趨勢與法規結構是什麼？

4.糖尿病神經病變市場主要供應商的市場佔有率為何？

5. 進入糖尿病神經病變市場合適的型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 糖尿病神經病變的盛行率和有效治療方法的需求
      • 提高對糖尿病診斷和治療的認知
      • 政府管理糖尿病神經病變的舉措
    • 抑制因素
      • 臨床試驗失敗率高，治療費用高
    • 機會
      • 擴大糖尿病神經病變的研究領域
      • 先進藥物輸送系統的開發
    • 任務
      • 與糖尿病神經病變治療相關的併發症
  • 市場區隔分析
    • 治療類型：藥物治療廣泛使用藥物來緩解疼痛、穩定神經功能
    • 疾病類型：週邊神經病變盛行率增加有利於糖尿病神經病變
    • 通路：網路藥局的出現成為便捷的醫療藥品通路
  • 市場趨勢分析
    • 繼續研究開發新治療方法並提高美洲糖尿病神經病變管理系統的核准
    • 亞太地區糖尿病盛行率不斷上升，專注於開發治療方法和設備的新興企業數量不斷增加
    • 政府支持措施改善歐洲、中東和非洲地區的糖尿病治療和護理
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析

第6章依治療類型分類的糖尿病神經病變市場

  • 藥品
  • 物理治療

第7章依疾病類型分類的糖尿病神經病變市場

  • 自主神經病變
  • 局部神經病變
  • 週邊神經病變
  • 近端神經病變

第8章糖尿病神經病變市場：依通路

  • 診所
  • 醫院
  • 網路藥房
  • 零售藥房

第9章北美及南美糖尿病神經病變市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區糖尿病神經病變市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的糖尿病神經病變市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Neuralace Medical 完成疼痛性糖尿病神經病變標籤擴展研究 (AT-PDN) 的註冊，為 FDA 批准和突破性糖尿病神經病變疼痛非侵入性治療鋪平道路
    • 撥款 140 萬英鎊用於開發糖尿病週邊神經病變的早期檢測
    • Horizo​​n Therapeutics核准FDA 批准更新 TEPEZZA (teprotumumab-TRBW) 的適應症語言，以指定在甲狀腺眼病 (TED) 患者中的使用，無論疾病活動度或持續時間如何。
    • Praetego 獲得美國國家眼科研究所 30 萬美元資助，用於開發治療糖尿病視網膜病變的新型口服藥物
    • Abbott、 Medtronic和 Nebro 正在開發 SCS 療法來治療週邊神經病變。

糖尿病患者 對於糖尿病患者

    • NeuroMetrix 推出週邊神經病變測試 DPNCheck 2.0
    • Tandem Diavites Care 完成對胰島素幫浦製造商 AMF Medical 的收購
    • 寶潔健康 (P&G Health) 與 IDF 合作解決糖尿病患者的周邊神經病變
    • Glenmark Pharma 推出治療糖尿病併發症的藥物
    • Regency Pharmaceuticals 宣布完成糖尿病週邊神經神經病變2 期試驗的入組工作，並獲得 930 萬美元的 B 系列資金籌措。
    • 醫療科技Start-UpsYostra Labs 已籌集 40 億盧比種子輪資金，用於幫助患有慢性病的患者。
    • FDA核准PENS 裝置治療糖尿病週邊神經病變相關疼痛
    • FDA核准Medtronic神經刺激設備治療糖尿病週邊神經病變疼痛
    • RMH 與澳洲糖尿病創新加速器中心合作
    • Withings 收購醫療設備製造商 Impet Medical

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-4348D129FA14

[181 Pages Report] The Diabetic Neuropathy Market size was estimated at USD 3.50 billion in 2023 and expected to reach USD 3.72 billion in 2024, at a CAGR 6.37% to reach USD 5.40 billion by 2030.

Diabetic neuropathy is a medical condition that damages the nerve and occurs in patients who have diabetes. High blood sugar (glucose) can damage nerves throughout the body, and diabetic neuropathy most frequently impacts nerves in the legs and feet. The increasing need for effective treatment for diabetic neuropathy, diagnosis of diabetes, and several government initiatives are the major driving factors for the growth of the diabetic neuropathy market. In addition, the growing awareness about diabetic neuropathy, increased healthcare spending, and a rise in pharmaceutical R&D spending contribute to developing novel drugs and systems for treating diabetic neuropathy. However, the high cost of medications used to treat diabetic neuropathy and the availability of alternative therapies may limit their use by diabetic patients. Production of advanced drug delivery systems and rising research in diabetic neuropathy are leading to the development of a breakthrough system for the effective management of diabetic neuropathy conditions, accelerating their use by patients in the forecast period.

KEY MARKET STATISTICS
Base Year [2023] USD 3.50 billion
Estimated Year [2024] USD 3.72 billion
Forecast Year [2030] USD 5.40 billion
CAGR (%) 6.37%

Treatment Type: Wide use of drugs for pharmacological treatment in diabetic neuropathy for alleviating pain and stabilizing nerve function

Drugs are used in the pharmacological treatment of diabetic neuropathy for alleviating pain and stabilizing nerve function. Pregabalin (Lyrica) and gabapentin (Neurontin) are popular anticonvulsant drugs for managing nerve pain in diabetic neuropathy patients. Among opioids, Tramadol (Ultram) is a centrally-acting opioid analgesic prescribed for moderate to severe pain associated with diabetic neuropathy. Physiotherapy, also known as physical therapy, is a non-pharmacological treatment that can help diabetic neuropathy patients improve their functional abilities and alleviate pain. Regular exercise and strengthening programs supervised by a certified physiotherapist can help improve muscle strength, balance, and endurance in diabetic neuropathy patients. Physiotherapy is often preferred to avoid side effects or contraindications.

Disorder Type: Preference for diabetic neuropathy due to increasing prevalence of peripheral neuropathy

Autonomic neuropathy affects the autonomic nervous system, which controls the involuntary functions of internal organs. Patients with this condition experience irregular heartbeat, urinary problems, digestive issues, and sexual dysfunction. Based on individual needs, treatments include medications to regulate blood pressure and heart rate, drugs for gastrointestinal motility, and medications to treat erectile dysfunction. Focal neuropathy is a disorder that affects a single nerve or group of nerves, causing severe pain or weakness localized in specific body parts such as hands, feet, or torso. The treatment addresses the underlying cause, such as compression or entrapment, including splinting or bracing for carpal tunnel syndrome or surgical intervention for severe cases. Peripheral neuropathy is the most common type, affecting the nerves of arms, hands, legs, and feet. Symptoms include numbness, tingling, pain, and weakness. Treatment preferences depend on individual needs, including over-the-counter pain relievers and prescription medications. Proximal neuropathy primarily affects the hip, buttock, or thigh muscles with symptoms such as severe pain and muscle weakness.

Distribution channel: Emergence of online pharmacies as a convenient distribution channel for medications prescribed for diabetic neuropathy management

Patients with diabetic neuropathy prefer clinics for convenience, affordability, and accessibility as they provide specialized care through a team of experts, including endocrinologists, podiatrists, and diabetes educators. Hospitals serve as comprehensive care providers for diabetic neuropathy patients requiring more extensive treatment or emergency interventions due to severe complications such as infections or ulcers. They offer access to equipment and multidisciplinary teams with expertise in treating complex cases. Online pharmacies have emerged as a convenient distribution channel for medications prescribed for diabetic neuropathy management, such as pain relievers, anti-seizure medications, and antidepressants. Patients prefer online pharmacies due to their ease of use, discreet delivery options, and competitive pricing compared to retail pharmacies. Retail pharmacies are popular for obtaining medications and over-the-counter supplements to manage diabetic neuropathy. They offer the advantage of face-to-face interaction with pharmacists who can provide personalized advice, medication management support, and access to a wide range of products.

Regional Insights

The Americas has a significant market in diabetic neuropathy due to the presence of a rising number of diabetic patients and increasing awareness related to diabetes disorders. Approvals from the FDA for new product development and ongoing research activities for developing novel and effective drugs are major growth factors in the Americas region. The Asia-Pacific region represents a growing landscape for the global diabetic neuropathy market due to increasing R&D activities in drug development. Several start-ups focusing on developing diabetic neuropathy treatments in the APAC region have contributed to the market growth. Government support to raise awareness regarding diabetes management and increased research and development of novel drugs and systems for relieving pain and efficient management of diabetic neuropathy conditions are creating the immense potential for the deployment of diabetic neuropathy drugs and systems in the EMEA region. Additionally, the introduction of innovative treatments and drug delivery systems is expected to contribute to the growth of the diabetic neuropathy market worldwide.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Diabetic Neuropathy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Diabetic Neuropathy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Diabetic Neuropathy Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AdventHealth, Alkem Labs, Astellas Pharma Inc., AstraZeneca PLC, Bauerfeind AG, Bayer AG, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Collegium Pharmaceutical, Inc., Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Grunenthal GmbH, Harmonium Pharma s.r.l., Lupin Limited, Medtronic PLC, Merck KGaA, NeuroMetrix, Inc., Nevro Corp., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Praetego, LLC, Regenacy Pharmaceuticals, Inc., Sanofi S.A., Stem Cell Care India, Teva Pharmaceutical Industries Ltd., The Procter & Gamble Company, Trevena, Inc., Vertex Pharmaceuticals Incorporated, Viatris Inc., and Winsantor, Inc..

Market Segmentation & Coverage

This research report categorizes the Diabetic Neuropathy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment Type
    • Drugs
      • Analgesics
        • Non-Steroidal Anti-Inflammatory Drugs
        • Opioids
        • Topical
      • Anticonvulsants
        • Gabapentin
        • Pregabalin
        • Topiramate
      • Antidepressant
        • Serotonin & Norepinephrine Reuptake Inhibitors
        • SSRIs
        • TCAs
    • Physiotherapy
  • Disorder Type
    • Autonomic Neuropathy
    • Focal Neuropathy
    • Peripheral Neuropathy
    • Proximal Neuropathy
  • Distribution channel
    • Clinics
    • Hospitals
    • Online Pharmacy
    • Retail Pharmacy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Diabetic Neuropathy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Diabetic Neuropathy Market?

3. What are the technology trends and regulatory frameworks in the Diabetic Neuropathy Market?

4. What is the market share of the leading vendors in the Diabetic Neuropathy Market?

5. Which modes and strategic moves are suitable for entering the Diabetic Neuropathy Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of diabetic neuropathy and the need for effective treatment methods
      • 5.1.1.2. Increasing awareness pertaining to diagnosis & treatment of diabetes
      • 5.1.1.3. Government initiatives for the management of diabetic neuropathy
    • 5.1.2. Restraints
      • 5.1.2.1. High failure rate in clinical trials and high cost of diabetic neuropathy treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Widening diabetic neuropathy research areas
      • 5.1.3.2. Development of advanced drug delivery systems
    • 5.1.4. Challenges
      • 5.1.4.1. Complications associated with diabetic neuropathy treatment
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Wide use of drugs for pharmacological treatment in diabetic neuropathy for alleviating pain and stabilizing nerve function
    • 5.2.2. Disorder Type: Preference for diabetic neuropathy due to increasing prevalence of peripheral neuropathy
    • 5.2.3. Distribution channel: Emergence of online pharmacies as a convenient distribution channel for medications prescribed for diabetic neuropathy management
  • 5.3. Market Trend Analysis
    • 5.3.1. Ongoing research for the development of novel treatments and rise in approvals for diabetic neuropathy management systems in the Americas
    • 5.3.2. Increasing prevalence of diabetes and emerging start-ups focused on developing diabetic neuropathy treatments and devices in the APAC region
    • 5.3.3. Supportive government initiatives to improve diabetes disease treatment and care in the EMEA region
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis

6. Diabetic Neuropathy Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Drugs
  • 6.3. Physiotherapy

7. Diabetic Neuropathy Market, by Disorder Type

  • 7.1. Introduction
  • 7.2. Autonomic Neuropathy
  • 7.3. Focal Neuropathy
  • 7.4. Peripheral Neuropathy
  • 7.5. Proximal Neuropathy

8. Diabetic Neuropathy Market, by Distribution channel

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Hospitals
  • 8.4. Online Pharmacy
  • 8.5. Retail Pharmacy

9. Americas Diabetic Neuropathy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Diabetic Neuropathy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Diabetic Neuropathy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Neuralace Medical Completes Enrollment of Painful Diabetic Neuropathy Label Expansion Study (AT-PDN) Paving the Way for FDA Clearance and a Breakthrough, Non-invasive Treatment for Diabetes related Neuropathic Pain
    • 12.3.2. GBP 1.4 million Awarded to Create early test for Diabetic Peripheral Neuropathy
    • 12.3.3. Horizon Therapeutics PLC announced FDA approval of an update to the indication language for TEPEZZA (teprotumumab-trbw) to specify its use in thyroid eye disease (TED) patients regardless of disease activity or duration
    • 12.3.4. Praetego awarded USD 300,000 by National Eye Institute to advance novel oral drug for diabetic retinopathy
    • 12.3.5. Abbott, Medtronic, and Nevro are developing SCS therapies to treat peripheral neuropathy treatment

a diabetic for diabetic

    • 12.3.6. NeuroMetrix launched peripheral neuropathy test DPNCheck 2.0
    • 12.3.7. Tandem Diabetes Care completed acquisition of insulin pump maker AMF Medical
    • 12.3.8. P&G Health, IDF partnered to address Peripheral Neuropathy in people with diabetes
    • 12.3.9. Glenmark Pharma launched drug for diabetic patients with comorbidities
    • 12.3.10. Regenacy Pharmaceuticals announced the completion of enrollment for phase 2 Study in diabetic peripheral neuropathy & USD 9.3 million series B financing
    • 12.3.11. Medtech startup Yostra Labs raised Rs 4Cr in a Seed round to help patients suffering from chronic disease
    • 12.3.12. FDA Clears PENS Device for pain related to diabetic peripheral neuropathy
    • 12.3.13. FDA cleared Medtronic's neurostimulator for diabetic peripheral neuropathy pain
    • 12.3.14. The RMH partnered with Australian Centre for Accelerating Diabetes Innovations
    • 12.3.15. Withings acquired Devicemaker Impeto Medical

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. DIABETIC NEUROPATHY MARKET RESEARCH PROCESS
  • FIGURE 2. DIABETIC NEUROPATHY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. DIABETIC NEUROPATHY MARKET DYNAMICS
  • FIGURE 7. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. DIABETIC NEUROPATHY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. DIABETIC NEUROPATHY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DIABETIC NEUROPATHY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY OPIOIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TOPICAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TOPICAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY GABAPENTIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY GABAPENTIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PREGABALIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PREGABALIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TOPIRAMATE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TOPIRAMATE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY SEROTONIN & NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY SEROTONIN & NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY SSRIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY SSRIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TCAS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY TCAS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY AUTONOMIC NEUROPATHY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY AUTONOMIC NEUROPATHY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY FOCAL NEUROPATHY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY FOCAL NEUROPATHY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PERIPHERAL NEUROPATHY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PERIPHERAL NEUROPATHY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PROXIMAL NEUROPATHY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY PROXIMAL NEUROPATHY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 79. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 80. AMERICAS DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 84. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 85. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 86. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 87. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 88. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 89. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 90. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 91. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 94. ARGENTINA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 95. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 98. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 99. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 100. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 101. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 102. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 103. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 104. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 105. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 108. BRAZIL DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 109. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 112. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 113. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 114. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 115. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 116. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 117. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 118. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 119. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 122. CANADA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 123. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 126. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 127. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 128. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 129. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 130. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 131. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 132. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 133. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 136. MEXICO DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 137. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 140. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 141. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 142. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 143. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 144. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 145. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 146. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 147. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 150. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 151. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 152. UNITED STATES DIABETIC NEUROPATHY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 169. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 172. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 173. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 174. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 175. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 176. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 177. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 178. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 179. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 182. AUSTRALIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 183. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 186. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 187. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 188. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 189. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 190. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 191. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 192. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 193. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 196. CHINA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 197. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 200. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 201. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 202. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 203. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 204. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 205. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 206. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 207. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 210. INDIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 211. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 214. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 215. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 216. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 217. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 218. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 219. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 220. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 221. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 224. INDONESIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 225. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 228. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 229. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 230. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 231. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 232. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 233. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 234. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 235. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 238. JAPAN DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 239. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 242. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 243. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 244. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 245. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 246. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 247. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 248. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 249. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 252. MALAYSIA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 253. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 256. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 257. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 258. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 259. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 260. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 261. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 262. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 263. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 266. PHILIPPINES DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 267. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 270. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 271. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 272. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 273. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 274. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 275. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 276. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 277. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 280. SINGAPORE DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 281. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 284. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 285. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 286. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 287. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 288. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 289. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 290. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 291. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 294. SOUTH KOREA DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 295. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 296. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 297. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 298. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 299. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 300. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 301. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 302. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 303. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 304. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 305. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 306. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 307. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 308. TAIWAN DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 309. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 310. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 311. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 312. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 313. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 314. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 315. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 316. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 317. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 318. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 319. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 320. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 321. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 322. THAILAND DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 323. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 324. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 325. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 326. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 327. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 328. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MILLION)
  • TABLE 329. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2018-2023 (USD MILLION)
  • TABLE 330. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY ANTICONVULSANTS, 2024-2030 (USD MILLION)
  • TABLE 331. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2018-2023 (USD MILLION)
  • TABLE 332. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY ANTIDEPRESSANT, 2024-2030 (USD MILLION)
  • TABLE 333. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2018-2023 (USD MILLION)
  • TABLE 334. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY DISORDER TYPE, 2024-2030 (USD MILLION)
  • TABLE 335. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 336. VIETNAM DIABETIC NEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 337. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 338. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 339. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 340. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 341. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2018-2023 (USD MILLION)
  • TABLE 342. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEUROPATHY MARKET SIZE, BY ANALGESICS, 2024-2030 (USD MIL